aMoon Fund

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, focused on developing innovative therapies to enhance the effectiveness of anti-cancer treatments. Established in 2015, the company has created a proprietary small molecule drug known as LUT014, which acts as a topical B-Raf inhibitor. This drug facilitates the use of epidermal growth factor receptor (EGFR) inhibitors while minimizing the common cutaneous side effects typically associated with such treatments. By addressing these side effects, Lutris Pharma aims to improve both the efficacy of anti-cancer therapies and the overall quality of life for patients undergoing treatment with EGFR inhibitors.

Lyfegen is a global provider of drug access, pricing, and rebate management services, with headquarters in Basel, Switzerland, and Boston, USA. The company offers a platform that assists healthcare payers, pharmaceutical companies, and medical technology providers in developing effective pricing agreements for medicines and streamlining the management of drug rebates. By leveraging advanced software, Lyfegen enables clients to collect, analyze, and reconcile diverse healthcare data, facilitating automation in value-based healthcare contracting. This approach aims to enhance access to treatments, improve patient health outcomes, and increase affordability in the healthcare sector.

MetaSight Diagnostics, a health technology company, is on a mission to develop affordable and precise liquid biopsy diagnostics for the early detection of a wide range of chronic and acute diseases by leveraging proprietary mass spectrometry technologies (metabolomics, lipidomics, and proteomics).

PrognomiQ is a technology company specializing in transforming the early detection and treatment of complex diseases like cancer. It generates comprehensive proteomic, genomic, and metabolomic data to provide insights into these conditions, aiming to enhance patient outcomes. The company's innovative approach involves developing advanced test products that improve understanding and management of health issues by integrating diverse health data types.

Air Doctor Ltd. operates an online marketplace that connects travelers with verified healthcare professionals in various locations. Founded in 2016 and based in Motza Illit, Israel, the platform allows users to search for and schedule appointments with doctors, dentists, emergency clinics, pharmacies, and other healthcare specialists. By providing access to practitioner profiles and patient reviews, Air Doctor simplifies the process of obtaining medical care abroad, ensuring that users can find professionals who speak their language and meet their specific needs. This service aims to enhance the experience of travelers by making healthcare access straightforward and efficient in unfamiliar destinations.

Operator of a data-driven healthcare startup intended to transform healthcare in rural communities through exceptional care, bringing better access and quality service to its patients. The company delivers tailored quality care through a team-based model, with resources and support for patients, inside and outside clinics, thereby enabling healthcare professionals to provide the support and care that patients need.

AltruBio is a biopharmaceutical company dedicated to the development of targeted antibody therapeutics aimed at treating cancer and immune-related inflammatory diseases. With its research and development foundation established in Taipei, Taiwan, since 2000, the company focuses on addressing unmet medical needs through innovative therapeutic solutions. AltruBio has developed an efficient discovery platform that identifies and validates novel antibody therapeutics. The company is actively advancing several potential therapeutic antibodies that target various conditions, including autoimmune diseases and multiple forms of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers. By leveraging its expertise in antibody-drug conjugate therapy and developing specialized linker payloads, AltruBio strives to improve patient outcomes and enhance recovery from immune-mediated diseases.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.

Nectin Therapeutics Ltd. is a biotechnology company founded in 2017 and based in Jerusalem, Israel. The company specializes in the development of novel monoclonal antibodies that target members of the Nectin family of receptors and ligands, which play significant roles in immune checkpoint mechanisms relevant to cancer immunotherapy. Nectin Therapeutics focuses on creating therapies for both solid and hematological malignancies by designing antibodies that can bypass the inhibitory pathways used by tumors, thereby enhancing the ability of immune cells to effectively eliminate cancer cells. Through its innovative approach, the company aims to improve patient outcomes in the fight against cancer.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Lyfegen is a global provider of drug access, pricing, and rebate management services, with headquarters in Basel, Switzerland, and Boston, USA. The company offers a platform that assists healthcare payers, pharmaceutical companies, and medical technology providers in developing effective pricing agreements for medicines and streamlining the management of drug rebates. By leveraging advanced software, Lyfegen enables clients to collect, analyze, and reconcile diverse healthcare data, facilitating automation in value-based healthcare contracting. This approach aims to enhance access to treatments, improve patient health outcomes, and increase affordability in the healthcare sector.

Theranica is a medical device company specializing in the development of electroceuticals that utilize neuromodulation therapy combined with advanced wireless technology. The company has created a proprietary wearable solution, specifically a non-invasive 'smart' patch, designed to address various medical conditions, with a primary focus on migraine headaches. This innovative product is controlled via a smartphone app, allowing for personalized and portable treatment options. The patch features a unique 'smart' chip that delivers electrical pulses to modulate the sensory nerves beneath the skin, offering patients an effective means of managing acute migraines. Theranica's solutions aim to provide affordable care and enhance the quality of life for individuals suffering from neurological pain.

Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

PrognomiQ is a technology company specializing in transforming the early detection and treatment of complex diseases like cancer. It generates comprehensive proteomic, genomic, and metabolomic data to provide insights into these conditions, aiming to enhance patient outcomes. The company's innovative approach involves developing advanced test products that improve understanding and management of health issues by integrating diverse health data types.

Satellite Bio is a company dedicated to advancing cell therapy and regenerative medicine through innovative approaches in synthetic biology and tissue engineering. It develops proprietary, off-the-shelf implantable satellite organs, which are designed as living therapeutic solutions aimed at addressing complex diseases. By focusing on creating these advanced cell therapies, Satellite Bio seeks to transform the lives of patients suffering from serious health conditions, offering new hope for effective treatment options.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

MOBILion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, focused on developing advanced analytical instrumentation for the detection and analysis of clinically relevant molecules. The company specializes in structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations with high sensitivity and resolution. This technology allows researchers to identify and analyze challenging biomolecules, including proteins, peptides, metabolites, glycans, and lipids, that traditional instruments often fail to detect. By improving the accuracy of diagnostic tests and enabling earlier disease detection, MOBILion's innovations support the development of better therapeutics and enhance the ability to monitor and treat medical conditions effectively. Since its incorporation in 2015, MOBILion Systems has aimed to transform disease prediction, diagnosis, and treatment through its state-of-the-art technology.

We're a digital healthcare company on a mission to enhance patients outcome by helping doctors and companies make better decisions through the generation of reliable synthetic data and by developing decision support systems

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

Biosplice Therapeutics is a company focused on medical research and development in tissue-level regeneration. Its platform, which originated from small molecule-based modulation of the Wnt signaling pathway, is designed to create therapeutics for a variety of degenerative diseases, including osteoarthritis and certain cancers. By discovering new biological targets and processes, Biosplice Therapeutics aims to develop innovative small molecule drugs that could provide curative therapies for multiple conditions. The company's objective is to enhance patient health through a comprehensive technology platform dedicated to modulating regenerative pathways.

AltruBio is a biopharmaceutical company dedicated to the development of targeted antibody therapeutics aimed at treating cancer and immune-related inflammatory diseases. With its research and development foundation established in Taipei, Taiwan, since 2000, the company focuses on addressing unmet medical needs through innovative therapeutic solutions. AltruBio has developed an efficient discovery platform that identifies and validates novel antibody therapeutics. The company is actively advancing several potential therapeutic antibodies that target various conditions, including autoimmune diseases and multiple forms of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers. By leveraging its expertise in antibody-drug conjugate therapy and developing specialized linker payloads, AltruBio strives to improve patient outcomes and enhance recovery from immune-mediated diseases.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

SOPHiA GENETICS is a healthcare technology company specializing in data-driven medicine. It offers the SOPHiA DDM™ Platform, a cloud-based SaaS solution that analyzes complex multimodal datasets from various diagnostic modalities to generate insights. With over 780 global clients, including hospitals, laboratories, and biopharma institutions across three continents, the company aims to make data-driven medicine the standard of care in healthcare and life sciences research.

PrognomiQ is a technology company specializing in transforming the early detection and treatment of complex diseases like cancer. It generates comprehensive proteomic, genomic, and metabolomic data to provide insights into these conditions, aiming to enhance patient outcomes. The company's innovative approach involves developing advanced test products that improve understanding and management of health issues by integrating diverse health data types.

MiNA Therapeutics Limited is a clinical-stage biotechnology company based in London, United Kingdom, focused on the design and development of small activating RNA medicines aimed at restoring normal cellular function. Founded in 2008, the company is dedicated to harnessing gene activation mechanisms to create therapeutic solutions for cancer and other severe diseases. Its product pipeline includes MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA paired with Pembrolizumab for advanced solid tumors. Through its innovative approach, MiNA Therapeutics aims to transform the treatment landscape, enabling healthcare professionals to effectively address challenging medical conditions.

MOBILion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, focused on developing advanced analytical instrumentation for the detection and analysis of clinically relevant molecules. The company specializes in structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations with high sensitivity and resolution. This technology allows researchers to identify and analyze challenging biomolecules, including proteins, peptides, metabolites, glycans, and lipids, that traditional instruments often fail to detect. By improving the accuracy of diagnostic tests and enabling earlier disease detection, MOBILion's innovations support the development of better therapeutics and enhance the ability to monitor and treat medical conditions effectively. Since its incorporation in 2015, MOBILion Systems has aimed to transform disease prediction, diagnosis, and treatment through its state-of-the-art technology.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

Nectin Therapeutics Ltd. is a biotechnology company founded in 2017 and based in Jerusalem, Israel. The company specializes in the development of novel monoclonal antibodies that target members of the Nectin family of receptors and ligands, which play significant roles in immune checkpoint mechanisms relevant to cancer immunotherapy. Nectin Therapeutics focuses on creating therapies for both solid and hematological malignancies by designing antibodies that can bypass the inhibitory pathways used by tumors, thereby enhancing the ability of immune cells to effectively eliminate cancer cells. Through its innovative approach, the company aims to improve patient outcomes in the fight against cancer.

Curesponse is a diagnostics company based in Tel Aviv-Yafo, Israel, founded in 2017. It specializes in developing a three-dimensional tissue culture system that models cancer growth and drug response. This innovative platform allows patients and clinicians to send tumor samples for testing, preserving the cancer tissue architecture, including vasculature and immune components. By accurately reflecting the cancer growth found in the body, Curesponse's technology enhances personalized cancer medicine, moving beyond traditional genomic predictions to assess functional responses in living patient cells. The company's goal is to match the appropriate drug to an individual’s specific tumor type, ultimately improving patient survival rates and reducing unnecessary medical interventions.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

AposHealth is focused on transforming the treatment of musculoskeletal conditions by addressing gait mechanics to alleviate pain and enhance mobility. Its flagship product, Apos®, is an FDA-cleared device designed to temporarily reduce knee pain associated with osteoarthritis, while also serving as a wellness tool for chronic lower back and hip pain. The Apos® system combines gait analysis with a personalized, foot-worn device and a tailored treatment plan. With a robust track record of over 110,000 patients treated and a 96 percent satisfaction rate, AposHealth is supported by numerous peer-reviewed studies that validate the effectiveness of its approach. By offering a drug-free and non-surgical solution, AposHealth empowers individuals to manage their discomfort and improve their quality of life.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

NanoGhost is a biotechnology company that specializes in advanced drug-delivery technology aimed at combating aggressive forms of cancer. Founded based on research from the Technion, which has secured patents for its innovation in the U.S. and Europe, NanoGhost utilizes adult stem cells to transport therapeutic agents directly to tumor sites. This targeted approach is designed to effectively shrink tumors, specifically in cases of small lung carcinoma, prostate cancer, and pancreatic cancer. By focusing on precise delivery, the company aims to alleviate pain associated with traditional radiology treatments, ultimately enhancing the quality of life for cancer patients.

Seer, Inc. is a life sciences company that specializes in nanoparticle technology solutions aimed at advancing proteomics research. The company offers Proteograph, an integrated system that includes consumables, automation instrumentation, and proprietary software for conducting proteomics analysis. Seer's products are designed for research applications, targeting academic institutions, life sciences laboratories, and biopharmaceutical companies for non-diagnostic and non-clinical uses. Additionally, Seer is focused on developing a health data platform that enhances early detection of chronic diseases by capturing and translating molecular insights from the proteome, thereby enabling healthcare professionals to identify conditions such as cancer and neurological disorders more accurately and rapidly. Founded in 2017 and headquartered in Redwood City, California, Seer was previously known as Seer Biosciences, Inc. before rebranding in July 2018.

Vocalis Health is a health technology company founded in 2019 and based in Tel Aviv, Israel, with an additional office in the United States. The company specializes in developing an artificial intelligence platform that utilizes vocal biomarkers to monitor and diagnose health conditions through voice analysis. Its technology enables healthcare providers to remotely screen and monitor patients affected by various voice-related diseases, including chronic respiratory and cardiac conditions, as well as mental health issues like depression. By employing machine learning and deep learning techniques, Vocalis Health's platform analyzes the acoustic features of voice recordings, providing valuable insights that help assess the severity and presence of health conditions, all accessible via a mobile application or web browser. The company was formed through the merger of Beyond Verbal and Healthymize.

Igentify Ltd is an Israeli company specializing in preventive healthcare through genomic products and services. Founded in 2016 by Galit Delmar and Yagil Tzur, Igentify is headquartered in Haifa. The company focuses on enhancing access to genomic information for clinicians, laboratories, and patients through its end-to-end digital genetic platform. One of its key offerings is FamilyFirst, an expanded carrier screening designed specifically for the Jewish and Israeli populations. Igentify's platform addresses the increasing demand for genomic medicine by digitizing various processes related to genetic testing, including patient education, consent collection, data analysis, and the delivery of personalized results. This approach aims to streamline and simplify the complexities often associated with genomic healthcare.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company based in Rehovot, Israel, founded in 2017. The company specializes in developing small molecule therapeutics for rare and aggressive cancers, focusing on genetically defined patient populations. Its lead product candidate is AL101, an intravenous gamma secretase inhibitor currently in Phase II clinical trials for treating recurrent/metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala Pharmaceuticals is developing AL102, an oral gamma secretase inhibitor in Phase I clinical trials for desmoid tumors. The company has a collaboration agreement with Novartis to develop AL102 for multiple myeloma. Ayala's approach involves using bioinformatics and next-generation sequencing to identify and address tumorigenic drivers of cancer, aiming to deliver targeted therapies to underserved patient populations.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Theranica is a medical device company specializing in the development of electroceuticals that utilize neuromodulation therapy combined with advanced wireless technology. The company has created a proprietary wearable solution, specifically a non-invasive 'smart' patch, designed to address various medical conditions, with a primary focus on migraine headaches. This innovative product is controlled via a smartphone app, allowing for personalized and portable treatment options. The patch features a unique 'smart' chip that delivers electrical pulses to modulate the sensory nerves beneath the skin, offering patients an effective means of managing acute migraines. Theranica's solutions aim to provide affordable care and enhance the quality of life for individuals suffering from neurological pain.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

Nobio Ltd. is a biotechnology company based in Petah Tikva, Israel, specializing in the development of innovative nano-polymer additives that provide protection against microbial infections. Its technology enables the transformation of both implantable and non-implantable devices into biofilm-resistant platforms. Nobio's product offerings include a universal bonding agent designed for strong adhesion to various dental surfaces and restorative materials, as well as flowable composites suitable for dental restorations and sealants. The core of Nobio's technology consists of potent particles embedded with highly-active antimicrobial structures that kill bacteria upon contact, effectively preventing medical device contamination indefinitely. This unique approach positions Nobio as a leader in the creation of durable antimicrobial materials and surfaces, enhancing safety and efficacy in medical and dental applications.

Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

Medial EarlySign Ltd is a healthcare technology company based in Kfar Malal, Israel, founded in 2009. The company develops an AI algorithmic platform designed to identify risks associated with critical health threats, particularly non-communicable diseases. Its primary products, AlgoMarkers and AlgoAnalyzer, utilize predictive engines to analyze routine medical data, such as blood test results and electronic health records, enabling healthcare organizations to diagnose large populations and deliver clinically relevant insights. By leveraging extensive patient data, Medial EarlySign provides clinical decision support and population health solutions that facilitate early predictions of outcomes related to various diseases, including cancers and metabolic disorders. This technology empowers healthcare providers to optimize care management, improve patient outcomes, and reduce costs through proactive and personalized approaches to health management.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.